Physiological evaluation of a new riluzole-derived compound as neuroprotective agent
Jessica Cazzola, Paolo Spaiardi, Serena Iannantuoni, Chiara Donati, Samuele Maramai, Mario Saletti, Antonio Nicolas Castagno, Giorgia Faravelli, Francesca Raffin, Arianna Trucco, Francesca Talpo, Maurizio Anzini, Gerardo Rosario Biella · FENS Forum 2024
Excitotoxicity is a central mechanism in the pathogenesis of different, currently incurable, neurodegenerative diseases. One treatment targeting excitotoxicity is Riluzole (Rilutek®), a drug capable of reducing glutamate release. Currently, Riluzole is available for patients with amyotrophic lateral sclerosis (ALS) to delay the progression of the disease. However, its efficacy diminishes in advanced stages of the pathology.The aim of this study has been to characterize the effect of a novel Riluzole-derived compound (VA945) as a potential neuroprotective drug, aiming at identify a more efficie
ePoster · Neuroscience